(Circulation. 2000;101:1760.)
© 2000 American Heart Association, Inc.
Brief Rapid Communications |
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors Modify the Inflammatory Response of Human Macrophages and Endothelial Cells Infected With Chlamydia pneumoniae
From the Department of Internal Medicine II (H.K., K.D., J.R., H.A.K.), the Institute of Microbiology (M.M.), the Department of Rheumatology (A.M.), Medical University of Lübeck; and the Department for Internal Medicine III (J.K.), University of Heidelberg, Germany.
Correspondence to K. Dalhoff, Med Klinik II, Medizinische Universität, Ratzeburger Allee 160, D-23538 Lübeck, Germany.
Background—In patients with atherosclerosis, hepatic hydroxymethylglutaryl coenzyme A reductase (CSE) inhibitors may reduce the activation of inflammation. Because Chlamydia pneumoniae infection has been linked to coronary artery disease through the induction of plaque inflammation, we investigated whether cerivastatin affects the infection rate of human macrophages and endothelial cells (ECs) and their proinflammatory activation after chlamydial infection.
Methods and Results—Macrophages were collected from the
alveolar compartment of 6 volunteers and 10 patients with chronic
bronchitis. ECs were obtained from 10 umbilical cords. The C.
pneumoniae strain CWL was incubated with macrophages or
ECs in the presence and absence of the CSE inhibitor
cerivastatin. The infection rate was determined by
immunofluorescence microscopy. The release of
monocyte chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8), and
tumor necrosis factor (TNF)-
was quantified by ELISA. The release of
oxygen radicals was determined by ferricytochrome assay. Infection
rates were tendentially lower after the preincubation of
macrophages with CSE inhibitors (17.2% versus
9.3% and 18.2% versus 10.4%, respectively; P=NS). The
secretion of MCP-1, IL-8, and TNF- by infected macrophages
from volunteers increased. Coincubation with cerivastatin resulted in
significantly lower MCP-1 and IL-8 production, whereas the
release of TNF- remained unaffected. Similar effects regarding
chemokine release were observed in ECs.
Conclusions—CSE inhibitors modify the inflammatory response of human immune cells to C. pneumoniae. This finding could be relevant for the therapeutic potential of CSE statins in patients with atherosclerosis and C. pneumoniae infection.
Key Words: inflammation • endothelium • atherosclerosis • infection
This article has been cited by other articles:
 |
|
 |
|
  F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett Statins and sepsis Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.B. J. Mancini, M. Etminan, B. Zhang, L. E. Levesque, J. M. FitzGerald, and J. M. Brophy Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2554 - 2560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Erkkila, M. Jauhiainen, K. Laitinen, K. Haasio, T. Tiirola, P. Saikku, and M. Leinonen Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in Mice Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3959 - 3962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Fessler, S. K. Young, S. Jeyaseelan, J. G. Lieber, P. G. Arndt, J. A. Nick, and G. S. Worthen A Role for Hydroxy-Methylglutaryl Coenzyme A Reductase in Pulmonary Inflammation and Host Defense Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 606 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Han, M. Parsons, X. Zhou, A. C. Nicholson, A. M. Gotto Jr, and D. P. Hajjar Functional Interplay Between the Macrophage Scavenger Receptor Class B Type I and Pitavastatin (NK-104) Circulation, November 30, 2004; 110(22): 3472 - 3479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P E Lazzerini, P L Capecchi, F Nerucci, A Fioravanti, F Chellini, M Piccini, S Bisogno, R Marcolongo, and F Laghi Pasini Simvastatin reduces MMP-3 level in interleukin 1{beta} stimulated human chondrocyte culture Ann Rheum Dis, July 1, 2004; 63(7): 867 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sabbatini, A. Pisani, F. Uccello, V. Serio, R. Seru, R. Paterno, B. Cianciaruso, G. Fuiano, and M. Andreucci Atorvastatin Improves the Course of Ischemic Acute Renal Failure in Aging Rats J. Am. Soc. Nephrol., April 1, 2004; 15(4): 901 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. McKay, B. P. Leung, I. B. McInnes, N. C. Thomson, and F. Y. Liew A Novel Anti-Inflammatory Role of Simvastatin in a Murine Model of Allergic Asthma J. Immunol., March 1, 2004; 172(5): 2903 - 2908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dechend, J. Gieffers, R. Dietz, A. Joerres, J. Rupp, F. C. Luft, and M. Maass Hydroxymethylglutaryl Coenzyme A Reductase Inhibition Reduces Chlamydia pneumoniae-Induced Cell Interaction and Activation Circulation, July 22, 2003; 108(3): 261 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kawashima, T. Yamashita, Y. Miwa, M. Ozaki, M. Namiki, T. Hirase, N. Inoue, K.-i. Hirata, and M. Yokoyama HMG-CoA Reductase Inhibitor Has Protective Effects Against Stroke Events in Stroke-Prone Spontaneously Hypertensive Rats Stroke, January 1, 2003; 34(1): 157 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Kalayoglu, P. Libby, and G. I. Byrne Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease JAMA, December 4, 2002; 288(21): 2724 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Di Napoli, A.A. Taccardi, M. Oliver, and R. De Caterina Statins and stroke: evidence for cholesterol-independent effects Eur. Heart J., December 2, 2002; 23(24): 1908 - 1921. [PDF]
|
|
|
|
 |
|
 S. Zeuke, A. J Ulmer, S. Kusumoto, H. A Katus, and H. Heine TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS Cardiovasc Res, October 1, 2002; 56(1): 126 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Palinski and S. Tsimikas Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1673 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stollberger and J. Finsterer Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis Clin. Vaccine Immunol., March 1, 2002; 9(2): 207 - 215. [Full Text] [PDF]
|
|
|
|
|
|
L. Wilhelmsen Inflammation, infection, and coronary heart disease Eur. Heart J., March 1, 2002; 23(5): 343 - 344. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wassmann, U. Laufs, K. Muller, C. Konkol, K. Ahlbory, A. T. Baumer, W. Linz, M. Bohm, and G. Nickenig Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 300 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takemoto and J. K. Liao Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Blankenberg, H. J. Rupprecht, C. Bickel, C. Espinola-Klein, G. Rippin, G. Hafner, M. Ossendorf, K. Steinhagen, and J. Meyer Cytomegalovirus Infection With Interleukin-6 Response Predicts Cardiac Mortality in Patients With Coronary Artery Disease Circulation, June 19, 2001; 103(24): 2915 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wassmann, U. Laufs, A. T. Baumer, K. Muller, K. Ahlbory, W. Linz, G. Itter, R. Rosen, M. Bohm, and G. Nickenig HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species Hypertension, June 1, 2001; 37(6): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Palinsk New Evidence for Beneficial Effects of Statins Unrelated to Lipid Lowering Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 3 - 5. [Full Text] [PDF]
|
|